Outset Medical Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
OM$4.22+2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity
Condensed Statement of Stockholders’ Equity
| Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance as of December 31, 2023 | 50,317 | $50 | $1,084,515 | $68 | $(961,747) | $122,886 |
| Issuance of common stock through employee stock purchase plan | 776 | 1 | 2,079 | — | — | 2,080 |
| Issuance of common stock for settlement of RSUs | 607 | 1 | 294 | — | — | 295 |
| Stock option exercises | 2 | — | 6 | — | — | 6 |
| Stock-based compensation expense | — | — | 8,203 | — | — | 8,203 |
| Unrealized loss on available-for-sale securities | — | — | — | (326) | — | (326) |
| Net loss | — | — | — | — | (39,944) | (39,944) |
| Balance as of March 31, 2024 | 51,702 | $52 | $1,095,097 | $(258) | $(1,001,691) | $93,200 |
Condensed Statement of Stockholders’ Equity
| Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance as of December 31, 2022 | 48,465 | $48 | $1,035,456 | $(564) | $(788,950) | $245,990 |
| Issuance of common stock through employee stock purchase plan | 307 | 1 | 4,593 | — | — | 4,594 |
| Issuance of common stock for settlement of RSUs | 282 | — | — | — | — | — |
| Stock option exercises | 162 | — | 684 | — | — | 684 |
| Stock-based compensation expense | — | — | 8,538 | — | — | 8,538 |
| Unrealized gain on available-for-sale securities | — | — | — | 451 | — | 451 |
| Net loss | — | — | — | — | (43,971) | (43,971) |
| Balance as of March 31, 2023 | 49,216 | $49 | $1,049,271 | $(113) | $(832,921) | $216,286 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.